Last updated: March 1, 2026
What is the Drug Identified by NDC 65757-0654?
The National Drug Code (NDC) 65757-0654 corresponds to Alectinib (brand name: Alecensa), a targeted therapy used primarily for treating ALK-positive non-small cell lung cancer (NSCLC). It is developed by Roche and approved by the FDA for specific indications.
Market Size and Dynamics
Current Market Landscape
-
Global Market Size: The global lung cancer therapeutics market was valued at approximately USD 8.4 billion in 2022. Within this, ALK inhibitors like Alectinib represent a significant segment, driven by increasing diagnosis and approvals.
-
U.S. Market Estimate: The U.S. accounts for roughly 30% of the global lung cancer drug market. The ALS-positive NSCLC subset constitutes about 3-5% of lung cancer cases, impacting the market size for drugs like Alecensa.
-
Key Competitors: Crizotinib (Xalkori), Brigatinib (Alunbrig), Ceritinib (Zykadia). Alectinib's position as the first-line treatment in certain indications boosts market share.
Drivers
- Rising incidence of NSCLC.
- Expansion of approved indications, including CNS metastases.
- Favorable clinical trial data demonstrating superior progression-free survival (PFS).
Limitations
- High drug prices.
- Competition from generic or biosimilar versions once patents expire.
- Pricing and reimbursement policies vary by country.
Pricing Overview
Current U.S. Price Points
- Average Wholesale Price (AWP): Approximately USD 17,500 per 150 mg capsule.
- Monthly Cost: Estimated at USD 10,000–USD 11,000, assuming daily dosing based on approved regimens.
Cost Factors
- Dosing: Typically 600 mg twice daily; treatment duration varies.
- Insurance Reimbursement: Skillfully negotiated by payers, impacting out-of-pocket costs.
- Price adjustments: Occur with manufacturer discounts and patient assistance programs.
International Pricing Variations
- Prices in Europe range from EUR 8,000 to EUR 12,000 per month, depending on country-specific negotiations.
- In low- and middle-income countries, pricing may be significantly lower due to healthcare infrastructure and approval status.
Market Penetration and Growth Forecasts
Short-term (Next 2 Years)
- Growth Rate: Expected compound annual growth rate (CAGR) of approximately 6-8%, driven by new approvals and increasing adoption.
- Market Penetration: Estimated to reach 70-80% among eligible ALK-positive NSCLC patients in the U.S. and select markets.
Long-term (Next 5 Years)
- Projected Market Size: Approaching USD 2–3 billion globally, contingent on continued clinical success and patent protections.
- Patent Status: Roche's patent protection until 2029, with biosimilar options possible thereafter.
Emerging Trends
- Development of combination regimens.
- Improved diagnostic capabilities leading to earlier detection.
- Potential price erosion from biosimilars post-patent expiry.
Price Projections (2023–2028)
| Year |
Estimated Price Range (USD/month) |
Key Factors |
| 2023 |
9,500 – 11,000 |
Stable prices with minor negotiations impact. |
| 2024 |
9,000 – 10,500 |
Competitive pressures from upcoming biosimilars. |
| 2025 |
8,500 – 10,000 |
Increased market competition; price adjustments. |
| 2026 |
8,000 – 9,500 |
Biosimilar entry may begin to erode pricing. |
| 2027 |
7,500 – 9,000 |
Market consolidation; pricing stabilization. |
| 2028 |
7,000 – 8,500 |
Patent expiry readiness; biosimilars influence pricing. |
Regulatory and Reimbursement Environment
- Payor policies increasingly favor cost-effective therapies.
- Price negotiations and risk-sharing agreements impact actual transaction prices.
- Special access programs reduce barrier for high-cost drugs in certain markets.
Key Takeaways
- The lung cancer therapeutics market, especially ALK inhibitors like Alectinib, is growing driven by increased diagnoses and enhanced clinical data.
- U.S. current pricing remains around USD 10,000 per month, with slight declines anticipated as biosimilars emerge.
- The estimated global market size could reach USD 2–3 billion over the next five years.
- Patent expiry and biosimilar competition will significantly influence future pricing dynamics.
FAQs
Q1: When is patent expiry for Alecensa?
A1: Roche's patent protections are expected to last until 2029, after which biosimilar competitors could enter the market.
Q2: Are biosimilars available for Alectinib?
A2: As of early 2023, biosimilars are not yet approved, but development is underway in several jurisdictions.
Q3: Which countries have the highest adoption of Alecensa?
A3: The U.S., European Union countries, and Japan lead in adoption, driven by approved indications and reimbursement frameworks.
Q4: How do reimbursement policies impact the drug's pricing?
A4: Reimbursement negotiations and coverage limits directly influence actual patient costs and can prompt price adjustments by manufacturers.
Q5: What is the potential impact of new clinical data on Alecensa's market?
A5: Positive results could expand indications, increase market share, and potentially raise prices temporarily.
Sources:
[1] MarketResearch.com. (2022). Lung Cancer Therapeutics Market Report.
[2] FDA Labels. (2022). Alecensa (Alectinib) Prescribing Information.
[3] IQVIA. (2022). Global Oncology Market Data.
[4] Roche. (2022). Alecensa Product Information.
